Casandra
Casandra Test Code QD74500Version 1 (DRAFT)
Performing Lab
Lab Quest DiagnosticsLab Test ID 36787
LeukoVantage®, Acute Myeloid Leukemia (AML)
Also known as: Myeloid NGS Panel AML, Abbott RealTime IDH2
Clinical Use
Order TestUse
The LeukoVantage® AML panel detects myeloid neoplasm‑associated mutations across 48 genes linked to AML, MDS, and/or MPNs for diagnosis, prognosis, and monitoring. It includes mutations such as ASXL1, FLT3, KIT, RUNX1, TET2, TP53, and targetable genes like FLT3, IDH1/2, and JAK2, aligned with guideline‑indicated prognostic and therapeutic relevance in acute myeloid leukemia.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
NGS (Targeted)
Biomarkers
Mutation (11 genes)
ASXL1FLT3KITRUNX1TET2TP53IDH1IDH2JAK2NPM1CEBPA
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Related Tests
Other tests from different labs that may be relevant
Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing
ARUP Laboratories
Myeloid Malignancies Mutation Panel by Next Generation Sequencing
ARUP Laboratories
IntelliGEN® Myeloid
Labcorp
Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel
ARUP Laboratories
Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing
ARUP Laboratories
MayoComplete Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53), Next-Generation Sequencing, Varies
Mayo Clinic Lab
MayoComplete Acute Myeloid Leukemia, 11-Gene Panel, Varies
Mayo Clinic Lab
Hereditary Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML) Panel
Prevention Genetics
Rapid AML Therapeutic Panel
NeoGenomics
Pillar oncoReveal Myeloid Sequencing Panel - A
MPLN